Skin and skin-structure infections are common in ambulatory settings. However, the efficacy of various antibiotic regimens in the era of community-acquired methicillinresistant Staphylococcus aureus (MRSA) is unclear.
n engl j med 372;12 nejm.org March 19, 2015 1094 T h e ne w e ngl a nd jou r na l o f m e dicine S kin and skin-structure infections (hereafter referred to as skin infections) are common conditions among patients seeking medical care in the United States, 1, 2 accounting for approximately 14.2 million outpatient visits in 2005 1 and more than 850,000 hospital admissions. 3 Skin infections are associated with considerable complications, including bacteremia, the need for hospitalization and surgical procedures, and death. 4, 5 Results of cultures of skin-infection lesions in the United States have shown that most of the infections are caused by methicillin-resistant Staphylococcus aureus (MRSA), 6, 7 but the efficacy of various antibiotic regimens in areas where communityassociated MRSA is endemic has not been defined. 8, 9 Either clindamycin or trimethoprim-sulfamethoxazole (TMP-SMX) is recommended because of the low cost and activity against communityassociated MRSA and methicillin-susceptible S. aureus (MSSA) strains of each of these drugs, 2,10-12 yet there are few comparative data on the safety and efficacy of these antibiotic agents for the treatment of skin infections. To address this limitation, we performed a randomized clinical trial comparing clindamycin and TMP-SMX for the treatment of uncomplicated skin infections at four U.S. centers located in areas of communityassociated MRSA endemicity.
Me thods

Study Design and Population
We performed a multicenter, prospective, randomized, double-blind clinical trial of clindamycin versus TMP-SMX for the treatment of uncomplicated skin infections. Patients were eligible if they had two or more of the following signs or symptoms for 24 or more hours: erythema, swelling or induration, local warmth, purulent drainage, and tenderness to pain or palpation. Patients were categorized as having cellulitis (defined as inflammation of the skin and associated skin structures without signs of a drainable fluid collection), abscess (defined as a circumscribed, drainable collection of pus), or both (if lesions of both cellulitis and abscess were present). Exclusion criteria were superficial skin infections (e.g., impetigo), skin infection at a body site that requires specialized management (e.g., perirectal, genital, or hand infection), a human or animal bite at the infection site, high fever (oral temperature, >38.5°C [>38.0°C in children 6 to 11 months of age]), receipt of immunosuppressive medications or the presence of an immunocompromising condition such as diabetes or chronic renal failure, morbid obesity (body-mass index [the weight in kilograms divided by the square of the height in meters], >40), surgical-site or prosthetic-device infection, and receipt of antibacterial therapy with antistaphylococcal activity in the previous 14 days. Patients were ineligible if they lived in a long-term care facility, had cancer or an inflammatory disorder that required treatment in the previous 12 months, or had major surgery in the previous 12 months. All the inclusion and exclusion criteria are listed in Table S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org. The full protocol and statistical-analysis plan are also available at NEJM.org.
Study Population, Stratification, and Randomization
From May 2009 through August 2011, patients were recruited at four locations (University of Chicago Medical Center, Chicago; San Francisco General Hospital, San Francisco; Harbor-UCLA [University of California, Los Angeles] Medical Center, Torrance, CA; and Vanderbilt University Medical Center, Nashville) from urgent care clinics, emergency departments, and affiliated clinics. All the patients or their parents or guardians provided written informed consent, and assent was obtained when age-appropriate. The protocol was approved by the institutional review board at each institution.
Patients were stratified into one of two groups on the basis of the characteristics of their infection before randomization: a group that included patients with a larger abscess or cellulitis (largerabscess-cellulitis group) or a group that included patients with a smaller abscess (limited-abscess group). The protocol and data-analysis plan prespecified that the limited-abscess group and the larger-abscess-cellulitis group be analyzed separately because their treatment assignments differed, in that the limited-abscess stratum included a placebo group. Patients who had a single abscess with a greatest diameter up to 5.0 cm (≤3.0 cm in patients 6 to 11 months of age and ≤4.0 cm in patients 1 to 8 years of age) were stratified into the limited-abscess group. All other patients, including those with an abscess greater than 5.0 cm in diameter (and proportionally smaller in young children), patients with two or more sites of skin infection, and patients with cellulitis without abscess (including erysipelas), were stratified into the larger-abscess-cellulitis group. The size of the abscess cavity was measured manually in three dimensions (width, length, and depth) and recorded on a standardized form. All abscesses were treated by means of incision and drainage. In this article, we describe the results for the larger-abscess-cellulitis group only.
Study Medication
After abscesses were drained (if present) and the size of the abscesses was determined, patients were randomly assigned in a 1:1 ratio to receive clindamycin or TMP-SMX. Variable-block randomization, with assignments made independently at each site, was performed by an independent contract research organization (EMMES) that developed the randomization code.
Clindamycin was given as two 150-mg tablets three times daily. TMP-SMX was given at doses of 160 mg of trimethoprim and 800 mg of sulfamethoxazole administered as two single-strength tablets twice daily. Patients randomly assigned to receive TMP-SMX were given two placebo pills for the midday dose. Pediatric doses were adjusted according to the body weight of the patient ( Table S2 in the Supplementary Appendix); liquid suspensions were available for pediatric dosing. Pills were overencapsulated to prevent identification by study staff and patients, and the taste of the clindamycin liquid preparations was masked with the use of flavoring both to prevent identification and to improve adherence. Patients were unaware of the treatment assignments, as were the study staff members, with the exception of the research pharmacists, who determined the correct dosing. The study medications were purchased by the study sponsor, the National Institute of Allergy and Infectious Diseases of the National Institutes of Health.
Microbiologic Studies and Demographic Data
To prevent investigator bias if treatment failures occurred, investigators were unaware of the microbiologic results, although the results could be obtained by an independent safety monitor on request. Swab cultures were obtained if there was a skin break, exudate, blister fluid, or other material that could be cultured. Nonsuppurative lesions were not cultured. Cultures, species identification of isolates, and susceptibility tests were performed by the clinical microbiology laboratory at each participating institution in accordance with methods approved by the Clinical and Laboratory Standards Institute. 13 External oversight for study activities was provided by two contract research organizations, Pharmaceutical Product Development (PPD) and the Division of Microbiology and Infectious Diseases Clinical Research Operations and Management Support (DMID-CROMS).
Patients were surveyed about demographic characteristics and coexisting conditions. Patients were seen at the end of treatment (day 12), at the test of cure (7 to 10 days after completion of the prescribed 10-day course of therapy), and at the 1-month follow-up (day 40). Information about clinical response and possible medication side effects was obtained with the use of standardized forms.
Statistical Analysis
The primary study outcome was clinical cure at the test-of-cure visit. Two primary efficacy analyses were performed: one in the intention-totreat population and the other in the population of patients who could be evaluated ( Fig. 1) . A lack of clinical cure was defined as a lack of resolution of signs or symptoms of infection, the occurrence of side effects that necessitated discontinuation of treatment with the study medication within the first 48 hours, or any one of the following before the test-of-cure visit: occurrence of a skin infection at a new body site, unplanned surgical treatment of the skin infection, or hospitalization related to the infection. The primary null hypothesis was that clindamycin and TMP-SMX would have equal rates of cure. The study was designed as a superiority trial with 80% power to detect an absolute difference between the two treatment groups of 10 percentage points in cure rates (85% vs. 95%) in the population that could be evaluated, at an alpha level of 0.05. Assuming a 20% attrition rate, we calculated that 524 patients (262 in each group) needed to be enrolled. The prespecified secondary outcomes were cure rates at the end of treatment and at the 1-month follow up visit; cure rates in the adult and pediatric populations; cure rates among patients with cellulitis, abscess, or mixed abscess and cellulitis (defined as separate lesions of abscess and cellulitis) at the test-ofcure visit; and adverse-event rates. Comparisons Table S3 in the Supplementary Appendix). There were no significant demographic differences between the groups. Abscess was present in 160 patients (30.5%), cellulitis in 280 (53.4%), and mixed abscess and cellulitis in 82 (15.6%); the lesions in 2 patients (0.4%) were not characterized. There were no significant differences between the groups with regard to clinical presentation, signs, or symptoms. Incision and drainage were performed in 44.5% of the patients. Detailed clinical information on the patients is provided in Table 1 .
Cultures were obtained for 296 patients (56.5%). The most common baseline isolate found in culture was S. aureus (217 of 524 patients, 41.4%) (Table 2); 27 of the 217 isolates (12.4%) were clindamycin-resistant, and 1 of 217 isolates (0.5%) was TMP-SMX-resistant. Stratification of culture results according to skin infection type is shown in Table S4 in the Supplementary Appendix.
Clinical Cure at the Test-of-Cure Visit
The rate of cure in the intention-to-treat population (524 patients) at the test-of-cure visit was 80.3% (95% confidence interval [CI], 75.2 to 85.4) in the clindamycin group and 77.7% (95% CI, 72.3 to 83.1) in the TMP-SMX group (difference, −2.6 percentage points; 95% CI, −10.2 to 4.9; P = 0.52) ( Table 3 ). In the population that could be evaluated (466 patients), the rate of cure was 89.5% (95% CI, 85.2 to 93.7) in the clindamycin group and 88.2% (95% CI, 83.7 to 92.7) in the TMP-SMX group (difference, −1.2 percentage points; 95% CI, −7.6 to 5.1; P = 0.77) (Fig. 2 ).
There were no significant differences between treatment groups, in either the intention-to-treat population or the population that could be evaluated, in subgroups consisting of children, adults, or patients with cellulitis, abscesses, or mixed abscess and cellulitis lesions ( Table 3 ). In addition, there were no significant between-group differences in subgroups of patients infected with S. aureus, MRSA, or MSSA in either the intentionto-treat population or the population that could be evaluated. In the population that could be evaluated, 11 of 15 clindamycin-treated patients with clindamycin-resistant S. aureus isolates were cured, as compared with 77 of 84 patients with susceptible isolates (73.3% [95% CI, 47.0 to 99.7] vs. 91.7% [95% CI, 85.0 to 98.3], P = 0.06).
Efficacy at 1 Month
Cure rates at the 1-month follow-up visit were similar for the clindamycin and TMP-SMX groups in the intention-to-treat population (193 
Adverse Events
Overall rates of adverse events were similar in the clindamycin and TMP-SMX groups (18.9% and 18.6%, respectively). The most common adverse events in the clindamycin and TMP-SMX groups were diarrhea (9.7% and 10.1%), nausea (2.3% and 2.7%), vomiting (2.3% and 1.6%), pruritis (1.5% and 1.2%), and rash (1.2% and 0.8%) ( Table S5 in the Supplementary Appendix). There were no cases of Clostridium difficile-associated diarrhea. Most adverse events were mild or moderate and resolved without sequelae. There were no treatment-associated serious adverse events (Table S6 ). The rates of treatment discontinuation due to adverse events were similar in the two groups (8.3% and 8.8%) ( 
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Discussion
We performed a double-blind, multicenter, randomized clinical trial to compare TMP-SMX and clindamycin, each of which is commonly recommended as empirical therapy for uncomplicated skin infections in the outpatient population with only minor or no coexisting conditions. 6, 7, 15, 16 The cure rates with TMP-SMX and clindamycin did not differ significantly. The cure rate with TMP-SMX ranged from 5 percentage points higher to 7 to 10 percentage points lower than the cure rate with clindamycin, on the basis of the 95% confidence intervals for rate differences in the intention-totreat population and the population that could be evaluated. This well-powered superiority trial did not show the superiority of either intervention. Although it is not appropriate to claim that Table S3 in the Supplementary Appendix. P values for all comparisons were nonsignificant (P>0.05 for all comparisons). The denominator for calculation of percentages is the number of patients in the intention-to-treat population for each treatment group. Plus-minus values are means ±SD. TMP-SMX denotes trimethoprim-sulfamethoxazole. † Race and ethnic group and information on Hispanic ethnic background were self-reported. ‡ Data were available for 263 patients in the clindamycin group and 259 in the TMP-SMX group. § Areas were calculated with the use of the formula for an ellipse ([length × width × π] / 4). ¶ The type of lesion was not known for 2 patients. ‖ Patients categorized as having mixed abscess and cellulitis lesions were those who had more than one lesion, with at least one abscess lesion that underwent incision and drainage and at least one cellulitis lesion that did not require incision and drainage. there are no differences on the basis of the negative result of the superiority test, important differences can reasonably be ruled out with the use of confidence intervals. Adverse-event rates with the two therapies were similar. Among all the patients, 46% had one or more abscesses larger than 5 cm in diameter (proportionally smaller in young children), all of which underwent incision and drainage. The 5-cm cutoff was based on data from a single-center observa-tional study involving children, in which abscesses larger than 5 cm were associated with treatment failure. 17 Although incision and drainage alone may be sufficient for treatment in many cases, there are likely to be subgroups in which antibiotic therapy is needed. Outcomes in antibiotictreated patients with abscesses in our relatively low-risk population could reflect either similar true efficacies or the adequacy of incision and drainage alone. Large placebo-controlled trials 
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T h e ne w e ngl a nd jou r na l o f m e dicine The New England Journal of Medicine are needed to further understand the role of active pharmacologic therapy in the treatment of patients with abscesses. The cure rates for TMP-SMX and clindamycin were similar among patients who had cellulitis as the sole lesion type. In the prespecified analysis of patients with cellulitis only, the point estimates of the TMP-SMX mean cure rates were 86.6% and 76.4% for the population that could be evaluated and the intention-to-treat population, respectively -rates that are 4.3 percentage points (95% CI, −13.1 to 4.6) to 4.5 percentage points (95% CI, −15.1 to 6.1) lower than the rates with clindamycin. In a post hoc analysis of patients with cellulitis with or without an abscess at another site, the cure rates were 87.9% (138 of 157 patients) with TMP-SMX and 90.9% (149 of 164) with clindamycin in the population that could be evaluated (difference, −3.0 percentage points [95% CI, −10.5 to 4.6]) and 77.1% (138 of 179) and 81.4% (149 of 183), respectively, in the intention-to-treat population (difference, −4.3 percentage points [95% CI, −13.5 to 4.8]). Our study was not powered to determine the superiority of one agent over the other in the subgroup of patients with cellulitis, but the data suggest that if there is a difference in outcome it is probably small. Moreover, in further support of the efficacy of TMP-SMX, the lower boundaries of the confidence intervals are above the 18 to 30% range for the inferiority of placebo to active agents cited for the outcome of cellulitis in the 2013 Food and Drug Administration guidance for acute bacterial skin and skin structure infections. 18, 19 The cause of cellulitis is incompletely understood, because a causative pathogen is not identified in most cases 20 ; this is consistent with our study, in which 80% of cellulitis lesions could not be cultured because skin was intact. Expert opinion 8 and empirical data 21, 22 suggest that cellulitis is most commonly caused by Streptococcus pyogenes. Our findings are provocative, because TMP-SMX has been considered a poor empirical choice for the treatment of cellulitis. Recent data show that S. pyogenes strains may be TMP-SMXsusceptible if low-concentration thymidine agar is used for testing. 23 Our results showing that TMP-SMX and clindamycin have similar efficacy in patients with cellulitis are consistent with these in vitro data.
With respect to adverse events, the rates were similar in the two groups. In particular, the rates of diarrhea were similar. The absence of C. difficile-associated diarrhea may stem from its relatively low incidence in patients with low disease severity and younger age, [24] [25] [26] characteristics that were typical of the patients in this trial. Rash has been a concern with TMP-SMX therapy 27 ; however, dermatologic side-effect rates were similar in the two groups. Overall adverse-event rates were similar in the pediatric and adult subgroups.
Our study has limitations. First, we excluded patients with serious coexisting conditions, and the outcomes of skin infections treated with clindamycin and TMP-SMX in populations with such conditions may differ. However, our investigation involved outpatients, the population in which approximately 95% of skin infections are treated, 28 and thus is generalizable to a large population. Second, we examined only two antibiotics, and the comparative efficacy and sideeffect profile of other oral medications are unclear. However, the two antibiotics we studied are those typically recommended by experts in areas of MRSA endemicity. 2,10-12 Third, patients were followed for 1 month after therapy was completed, which is a strength in comparison with studies lacking a documented follow-up visit but is also a limitation. S. aureus infections are often recurrent, 29, 30 and 1 month of follow-up may be inad- The graph shows the proportion of patients cured by the time of the test-of-cure visit in the intention-totreat population and the population that could be evaluated. The actual confidence level was 95.60% after adjustment for interim analyses. equate for assessing the efficacy of a drug in preventing recurrent disease. Fourth, the dosages of clindamycin and TMP-SMX for skin infections are not well defined. Some have suggested using twice the dose we used (see, e.g., ClinicalTrials.gov number NCT00729937), whereas others have recommended the same dose. 8 Our data show that the efficacy of TMP-SMX doses of 160 mg and 800 mg does not differ significantly from that of a commonly recommended dose of clindamycin -specifically, 300 mg three times daily. 8 Finally, the proportions of patients who had an S. aureus isolate that was resistant to clindamycin or TMP-SMX (5.2% and 0.2%, respectively) were relatively low. Given the low prevalence of resistance, its contribution to treatment failure is unclear, although there was a trend toward a lower clindamycin cure rate for infections caused by clindamycin-resistant S. aureus versus clindamycin-susceptible isolates (73.3% vs. 91.7%, P = 0.06), which also raises important questions about the spontaneous response rate. The number of patients with inducible clindamycinresistant isolates was even smaller (three patients in the population that could be evaluated), which precluded making conclusions about its role in treatment failure.
Our study has important strengths. It was a double-blind, randomized clinical trial accompanied by detailed drug accountability (i.e., storage, handling, and dispensing of study drugs, as well as documentation of their administration), detailed systematic reviews of adverse drug effects, and relatively low rates of attrition (10.5%). We included both adults and children, which is of critical importance given that skin infections are highly prevalent among persons of all ages. 7, 28 Finally, the populations studied were ethnically and geographically diverse. In summary, we found no significant differences between the efficacy of clindamycin and that of TMP-SMX for the treatment of uncomplicated skin infections in children and adults with few or no major coexisting conditions. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
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